The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population.
Journal
The Journal of clinical psychiatry
ISSN: 1555-2101
Titre abrégé: J Clin Psychiatry
Pays: United States
ID NLM: 7801243
Informations de publication
Date de publication:
02 07 2019
02 07 2019
Historique:
received:
22
08
2018
accepted:
04
03
2019
entrez:
3
7
2019
pubmed:
3
7
2019
medline:
22
4
2020
Statut:
epublish
Résumé
Current evidence suggests that women are more sensitive to the effects of cannabinoids. The aim of this study was to investigate the relevance of sex in the association of synthetic cannabinoid (SC) use with psychosis and agitation. A retrospective chart review was conducted for patients admitted to a psychiatric unit (2014-2016) to extract information on demographic factors, use of substances, clinical symptoms, and pharmacologic treatments. Study groups were defined as SC users (anyone who reported use of SCs over the past 3 months), cannabis users (positive toxicology screen for Δ⁹-tetrahydrocannabinol [THC]), and controls (those who denied use of SCs over the past 3 months and had negative toxicology for THC). Digital charts of 983 patients were reviewed. A total of 162 subjects reported use of SCs over the past 3 months (76% male), and 292 subjects had positive toxicology screen for THC (67% male). A total of 38.9% of SC users (n = 63) had positive urine toxicology screen for THC. SC users had higher risks of psychotic presentations (adjusted odds ratio [AOR] = 3.390; 95% CI, 1.390-8.267) and agitation (AOR = 4.643; 95% CI, 1.974-10.918) compared to the controls. While women had lower rates of psychosis than men in the cannabis and control groups, the rates were markedly potentiated with SC use to high levels (79%) approximately equal to that seen in men (80%). There was also a significant interaction between SC use and sex for agitation (AOR = 0.308; 95% CI, 0.117-0.808). Female SC users were significantly more agitated than male SC users (73.7% vs 47.6%, respectively, P = .005). SC users are more likely than nonusers to be psychotic or agitated in an inpatient setting. The potentiated rates of psychosis and agitation with SC use in women suggest that they may have a greater sensitivity to these synthetic compounds..
Sections du résumé
BACKGROUND
Current evidence suggests that women are more sensitive to the effects of cannabinoids. The aim of this study was to investigate the relevance of sex in the association of synthetic cannabinoid (SC) use with psychosis and agitation.
METHODS
A retrospective chart review was conducted for patients admitted to a psychiatric unit (2014-2016) to extract information on demographic factors, use of substances, clinical symptoms, and pharmacologic treatments. Study groups were defined as SC users (anyone who reported use of SCs over the past 3 months), cannabis users (positive toxicology screen for Δ⁹-tetrahydrocannabinol [THC]), and controls (those who denied use of SCs over the past 3 months and had negative toxicology for THC).
RESULTS
Digital charts of 983 patients were reviewed. A total of 162 subjects reported use of SCs over the past 3 months (76% male), and 292 subjects had positive toxicology screen for THC (67% male). A total of 38.9% of SC users (n = 63) had positive urine toxicology screen for THC. SC users had higher risks of psychotic presentations (adjusted odds ratio [AOR] = 3.390; 95% CI, 1.390-8.267) and agitation (AOR = 4.643; 95% CI, 1.974-10.918) compared to the controls. While women had lower rates of psychosis than men in the cannabis and control groups, the rates were markedly potentiated with SC use to high levels (79%) approximately equal to that seen in men (80%). There was also a significant interaction between SC use and sex for agitation (AOR = 0.308; 95% CI, 0.117-0.808). Female SC users were significantly more agitated than male SC users (73.7% vs 47.6%, respectively, P = .005).
CONCLUSIONS
SC users are more likely than nonusers to be psychotic or agitated in an inpatient setting. The potentiated rates of psychosis and agitation with SC use in women suggest that they may have a greater sensitivity to these synthetic compounds..
Identifiants
pubmed: 31265768
doi: 10.4088/JCP.18m12539
pmc: PMC8445109
mid: NIHMS1735398
doi:
pii:
Substances chimiques
Cannabinoids
0
Psychotropic Drugs
0
Dronabinol
7J8897W37S
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR001434
Pays : United States
Informations de copyright
© Copyright 2019 Physicians Postgraduate Press, Inc.
Références
Psychopharmacologia. 1972;25(3):218-28
pubmed: 5065158
Br J Pharmacol. 2010 Jun;160(3):724-35
pubmed: 20590575
Exp Clin Psychopharmacol. 2015 Dec;23(6):415-21
pubmed: 26461168
Drug Alcohol Depend. 2017 Apr 01;173:117-125
pubmed: 28219802
Adv Exp Med Biol. 1977;85B:251-64
pubmed: 563665
J Med Toxicol. 2015 Dec;11(4):415-21
pubmed: 25652342
Drug Alcohol Depend. 2014 Mar 1;136:85-91
pubmed: 24440051
Transl Psychiatry. 2012 Mar 20;2:e94
pubmed: 22832859
Psychopharmacologia. 1975;41(3):277-84
pubmed: 168604
Psychiatry Res. 2014 Mar 30;215(3):528-32
pubmed: 24461684
Australas Psychiatry. 2016 Dec;24(6):598-601
pubmed: 27558216
Addiction. 2013 Mar;108(3):534-44
pubmed: 22971158
Br J Pharmacol. 1972 Apr;44(4):794-804
pubmed: 5064930
Transcult Psychiatry. 2015 Dec;52(6):827-39
pubmed: 26045571
J Dual Diagn. 2016 Jul-Dec;12(3-4):244-251
pubmed: 27710762
Schizophr Bull. 2016 Sep;42(5):1262-9
pubmed: 26884547
Drug Alcohol Depend. 2014 Nov 1;144:12-41
pubmed: 25220897
Drug Alcohol Depend. 2013 Jun 1;130(1-3):101-8
pubmed: 23182839
Lancet. 2007 Jul 28;370(9584):319-28
pubmed: 17662880
Life Sci. 1973 Jul 1;13(1):75-85
pubmed: 4796256
Toxicol Appl Pharmacol. 1975 May;32(2):399-417
pubmed: 1171539
Psychopharmacologia. 1973 Oct 23;33(1):53-70
pubmed: 4358666
Science. 1978 Mar 31;199(4336):1459-61
pubmed: 415367
J Pharmacol Exp Ther. 2007 Mar;320(3):1097-105
pubmed: 17172531
Br J Pharmacol. 2007 Nov;152(5):795-804
pubmed: 17891164
Addict Behav. 2010 Feb;35(2):102-10
pubmed: 19818563
Br J Pharmacol. 1977 Nov;61(3):371-9
pubmed: 201320
Physiol Behav. 1972 Oct;9(4):585-7
pubmed: 4677621
Behav Biol. 1975 May;14(01):1-20
pubmed: 166635
Psychopharmacologia. 1975 May 28;42(2):195-200
pubmed: 1172250
Schizophr Bull. 2015 Nov;41(6):1397-402
pubmed: 25841041
J Psychopharmacol. 2016 Dec;30(12):1321-1330
pubmed: 27462088
MMWR Morb Mortal Wkly Rep. 2016 Jul 15;65(27):692-5
pubmed: 27413997
Biol Psychiatry. 2010 Feb 1;67(3):255-62
pubmed: 19897178
J Pharmacol Exp Ther. 2012 Mar;340(3):787-800
pubmed: 22182934
Am J Drug Alcohol Abuse. 2010 Nov;36(6):311-9
pubmed: 20678028
Psychopharmacology (Berl). 2016 Sep;233(18):3331-40
pubmed: 27422568
Aust N Z J Psychiatry. 2010 Jan;44(1):85-93
pubmed: 20073570
Psychiatry Res. 2013 Nov 30;210(1):368-70
pubmed: 23919899
Life Sci I. 1972 Feb 1;11(3):103-11
pubmed: 4675887
Compr Psychiatry. 2016 Aug;69:169-78
pubmed: 27423358
World Psychiatry. 2016 Oct;15(3):195-204
pubmed: 27717258
Eur J Pharmacol. 2001 Oct 26;430(1):41-7
pubmed: 11698061
Psychopharmacology (Berl). 1976 Jul 28;48(2):175-9
pubmed: 188060
Psychopharmacology (Berl). 1976 May 5;47(1):59-64
pubmed: 986662
Biol Psychiatry. 2016 Apr 1;79(7):549-56
pubmed: 26386480
Psychol Med. 2013 Jan;43(1):155-67
pubmed: 22564907
Hum Psychopharmacol. 2017 May;32(3):
pubmed: 28557062
J Med Toxicol. 2016 Dec;12(4):335-340
pubmed: 27255136
Drug Alcohol Depend. 2014 Oct 1;143:22-8
pubmed: 25131716
Life Sci. 2014 Feb 27;97(1):78-90
pubmed: 24412391
Drug Alcohol Depend. 2010 Sep 1;111(1-2):120-7
pubmed: 20510550
Br J Psychiatry. 2009 Dec;195(6):488-91
pubmed: 19949195
Am J Psychiatry. 2018 Mar 1;175(3):225-231
pubmed: 29241357